An emerging cancer treatment also helps prevent cells from turning into viral factories by interfering with HIV infection processes inside the cell, according to a recent study.
A new immunotherapy developed by investigators at Northwestern University dramatically extends the survival time of mice with triple negative breast cancer, one of the most aggressive and difficult-to-treat forms of breast cancer.
Cancer patients with other comorbidities have a higher risk of dying from complications due to COVID-19, and should discuss the risks and benefits of continuing cancer treatment with their physician, according to a recent study.
A novel drug called enzalutamide may extend overall survival for men with nonmetastatic, castration-resistant prostate cancer, according to findings from clinical trial published in The New England Journal of Medicine.
A novel compound using diphtheria toxin to attack a signaling pathway implicated in as many as 50 percent of cancers slowed tumor growth, according to a recent study.
A protein called mDia2 is vital for proper bone marrow transplantation, according to a new study.
Machine-learning technology could help pathologists more accurately assess how a patient’s immune system is responding to breast cancer, according to a recent series of reports authored in part by Feinberg faculty.
A genetic screen has revealed previously unknown regulators of Foxp3, a transcription factor that, when deactivated, may improve patient response to aggressive cancers.
Northwestern Medicine scientists have discovered an alternate mechanism for aberrant gene splicing that contributes to T-cell lymphoblastic leukemia, according to a recent study.
In women with early-stage breast cancer, Northwestern Medicine investigators found chemoendocrine therapy was associated with greater cognitive impairment at three and six months compared to endocrine therapy alone.